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ABSTRACT
The COVID-19 (caused by severe acute respiratory 
syndrome coronavirus 2 (SARS- CoV-2)) epidemic started 
in Wuhan (Hubei Province, China) in mid- December 2019 
and quickly spread across the world as a pandemic. As 
a key to tracing the disease and to implement strategies 
aimed at breaking the chain of disease transmission, 
extensive testing for SARS- CoV-2 was suggested. 
Although nasopharyngeal/oropharyngeal swabs are the 
most commonly used biological samples for SARS- CoV-2 
diagnosis, they have a number of limitations related to 
sample collection and healthcare personnel safety. In this 
context, saliva is emerging as a promising alternative 
to nasopharyngeal/oropharyngeal swabs for COVID-19 
diagnosis and monitoring. Saliva collection, being a 
non- invasive approach with possibility for self- collection, 
circumvents to a great extent the limitations associated 
with the use of nasopharyngeal/oropharyngeal swabs. 
In addition, various salivary biomarkers including the 
salivary metabolomics offer a high promise to be useful 
for better understanding of COVID-19 and possibly in the 
identification of patients with various degrees of severity, 
including asymptomatic carriers. This review summarises 
the clinical and scientific basis for the potential use of 
saliva for COVID-19 diagnosis and disease monitoring. 
Additionally, we discuss saliva- based biomarkers and 
their potential clinical and research applications related 
to COVID-19.
INTRODUCTION
An epidemic of a new coronavirus with pneumonia- 
like symptoms started in Wuhan (Hubei Province, 
China) in December of 2019. The COVID-19, 
identified to be caused by severe acute respira-
tory syndrome coronavirus 2 (SARS- CoV-2) infec-
tion,1 2 spread very quickly across the world and 
was declared a pandemic by WHO. As of 24 May 
2020, the COVID-19 infection has accounted for 
>5 000 000 cases with >3 00 000 deaths reported 
worldwide.3 The fast spread of this disease is related 
to its highly infectious nature, and the disease is 
suggested to be transmitted through saliva droplets 
and nasal discharge.4 In order to trace the disease 
and to implement strategies aimed at breaking the 
chain of disease transmission, WHO has recom-
mended extensive testing for COVID-19. This is 
particularly important as approximately 80% of 
the disease transmission has been reported to be 
related to asymptomatic cases.4 Here, we suggest 
that saliva- based testing can be an alternative to the 
more widely used nasopharyngeal/oropharyngeal 
swabs for COVID-19 diagnosis and disease moni-
toring. In addition, we discuss unique opportunities 
and possible challenges related to the saliva- based 
research activities on COVID-19.
SALIVA AS A POTENTIAL DIAGNOSTIC FLUID 
FOR SARS-COV-2
The emergence of the COVID-19 pandemic has 
highlighted the need for multiple diagnostic strat-
egies to efficiently evaluate potential cases in order 
to provide information on population exposure 
and immunity. These tools currently include virus 
molecular testing and rapid host immune response 
assays.
Saliva is a biological fluid in which SARS- CoV-2 
can be found and for this reason saliva has been 
taken into consideration in the diagnosis of 
COVID-19. The presence of SARS- CoV-2 in 
saliva may be related to different sources such as 
i) virus entry to the oral cavity from lower/upper 
respiratory tract,1 5 ii) access to the mouth via oral 
cavity- specific crevicular fluid or iii) release of viral 
particles in the oral cavity via salivary ducts from 
the infected salivary glands6 (figures 1 and 2). The 
latter observation may explain how COVID-19 
transmission can occur through asymptomatic cases 
with no obvious infection in the respiratory tracts.
The major salivary glands (parotid, submandib-
ular and sublingual glands) are the major contrib-
utors of saliva secretion (figure 2). Approximately 
600–1000 mL of saliva, containing molecules such 
as growth factors, cytokines and secretory IgA, is 
secreted each day from the human salivary glands.7 
Of note, the unique salivary glands structure 
with rich surrounding blood circulation has been 
suggested to facilitate the exchange of molecules in 
the blood into the salivary acini and subsequently 
in the saliva.8 Saliva has been studied thoroughly 
as a potential diagnostic tool and it is expected to 
become a substitute for other biological fluids such 
as serum or urine in disease diagnosis.8 9 Compared 
with other diagnostic fluids, saliva sampling has 
the advantages and disadvantages as mentioned in 
table 1.
The diagnostic potential of saliva was estab-
lished by studies that revealed that, like serum, 
saliva contains hormones, antibodies, growth 
factors, enzymes, microbes and their products that 
can enter saliva through blood via passive diffu-
sion, active transport or extracellular ultra filtra-
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monitoring the physiological function of the body.10 Although 
the low concentration of some analytes in saliva compared with 
the blood previously proved challenging, the advent of highly 
sensitive molecular methods and nanotechnology have to a large 
extent circumvented this limitation.
Collection of saliva can be done in several ways, such as spitting 
out, collection with the help of sponge- like device and directly 
from the salivary gland duct.7 The spitting out technique is the 
cheapest one, and the saliva sample thus collected also includes 
nasopharyngeal/oropharyngeal/airway secretions. Sponge- like 
devices provide relatively more pure saliva, but this technique 
requires special equipment which is not always widely avail-
able. Saliva collected directly from the ducts of major salivary 
gland provides pure saliva, but the the collection process is time 
consuming and requires special equipment. Several protocols 
and approaches are available for DNA and RNA extraction and 
antibody detection, providing good performances regardless of 
sampling technique.11
The diagnostic topic of saliva (called ‘Salivaomics’) includes 
the study of salivary proteins (proteomics), the study of sali-
vary RNAs (transcriptomics), the study of salivary metabolites 
(metabolomics), the study of salivary microRNAs (microRNA) 
and the study of salivary microbiota (microbiome).12
To date, saliva is used for the diagnosis of several diseases 
including hereditary diseases, autoimmune diseases, malignan-
cies, infections, dental caries and periodontal disease.13 14 Addi-
tionally, saliva can be used for diagnosing oral diseases with 
relevance for systemic diseases or for monitoring of levels of 
hormones, drugs and bone turnover markers.12
Diagnosis of saliva- based viral infections depends on the pres-
ence of viral DNA, RNA, microRNA, antigens or host antibodies 
in saliva. In this context, some viruses have been detected in 
saliva up to 29 days after infection, indicating that a saliva- based 
non- invasive diagnostic platform can be useful for early diag-
nosis and for monitoring the disease and treatment.9 15
SALIVA TESTING FOR SARS-COV-2
SARS-CoV-2 detection using reverse-transcription PCR
SARS- CoV-2 is an enveloped, positive single- stranded RNA virus 
consisting of a core of RNA genome associated with nucleocapsid 
protein (N) and surrounded by a phospholipid membrane with 
three main viral structural proteins, spike surface glycoprotein 
(S), small envelope protein (E) and matrix protein (M).16 Nucle-
otide sequences within a number of SARS- CoV-2 genes such as 
E, RdRp, N1 and N2 and S can be used as detection targets 
for RT- PCR- based test methods.17 On the other hand, detection 
of SARS- CoV-2 antigens and/or immunoglobulins against them 
form the basis for enzyme immunoassays.17
Presently, RT- PCR is the most commonly used diagnostic test 
for the detection of SARS- CoV-2 RNA in the biological samples. 
For large- scale testing as in the case of SARS- CoV-2, proper 
selection of the type and the site of biological specimen collec-
tion is crucial for obtaining reliable test results.18 Biological 
samples from the upper (such as nasopharyngeal swabs, oropha-
ryngeal swabs, throat swabs, nasal swabs) and lower (such as 
tracheal aspirates and brochoalveolar lavage) respiratory tracts 
can be used for the detection of SARS- CoV-2 with varying 
degree of test sensitivity19–21 (figure 2). Tracheal aspirates and 
bronchoalveolar lavage, although more reliable for SARS- CoV-2 
detection, are the less preferred specimens as compared with 
the nasopharyngeal/oropharyngeal swabs due to technical 
complexity in obtaining these samples.21 Currently, nasopharyn-
geal/oropharyngeal swabs where virus samples are collected by 
respectively rubbing the nasopharyngeal wall and the posterior 
pharynx/tonsillar areas with minitip swabs, are routinely used 
for SARS- CoV-2 detection17 (figure 2).
Despite the widespread use, the collection of nasopharyngeal/
oropharyngeal swabs has a number of limitations.22 23 The collec-
tion of these swabs is less acceptable to patients as compared 
with non- invasive methods like saliva collection, as it tends to 
cause patient discomfort and even bleeding. Patient acceptance 
is highly desirable for test methods where multiple testing is 
needed for disease monitoring and follow- up, as in the case of 
COVID-19. Furthermore, the risk for disease transmission to 
the healthcare personnel when collecting these samples is high 
as it requires active involvement of the test taker. Additionally, 
Figure 1 Schematic illustration demonstrating clinical implications 
and various sources of severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) in saliva. Inset: a suggested mechanism for SARS- CoV-2 
entry into the salivary gland cells—the viral spike protein binds with 
the ACE2 receptor on the surface of the cell, followed by its priming 
with serine protease TMPRSS2 and subsequent entry into the cells. After 
replication and packaging, multiple new virus particles are released 
from the cells in saliva.
Figure 2 Schematic illustration demonstrating major salivary glands 
(parotid, submandibular and sublingual) and their respective ducts, 
oropharynx and nasopharynx, and approximate anatomic locations for 
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collection of these samples demands the use of personal protec-
tive and healthcare resources, both of which tend to be in short 
supply in a pandemic like COVID-19.
Saliva as a biological fluid for molecular detection of SARS-
CoV-2
Saliva is emerging as a promising alternative to nasopharyn-
geal/oropharyngeal swabs for COVID-19 diagnosis and moni-
toring.24 25 Indeed, the use of saliva as a biological specimen for 
SARS- CoV-2 testing to a great extent circumvents the above- 
mentioned limitations associated with the use of nasopharyn-
geal/oropharyngeal swabs. With clear instructions, patients can 
self- collect saliva samples. This is highly desirable in an outbreak 
in order to minimise the burden on healthcare personnel, the use 
of personal protective equipment and to allow serial sampling 
required for disease monitoring. A recent study has reported that 
self- collection of saliva sample for SARS- CoV-2 testing is feasible 
and can produce reliable test results.24
The potential use of saliva for SARS- CoV-2 detection is 
scientifically well founded. Saliva is considered to be a good 
reservoir for viruses that originate from oral shedding, and 
secretions from the lower respiratory tract, nasopharynx and 
possibly infected salivary glands22 23 (figure 1). Indeed, Chen et 
al were able to detect SARS- CoV-2 RNA in three out of four 
saliva samples directly collected from the salivary gland ducts, 
thereby precluding contamination from respiratory secretions, 
of critically ill cases.26 Together with the demonstration of ACE2 
expression,27 a main surface receptor type for SARS- CoV-2,1 in 
the salivary gland, the above findings substantiate the idea that 
salivary gland could be one of the sources for SARS- CoV-2 in 
saliva. In line with this observation, recent studies by To et al 
demonstrated the presence of live SARS- CoV-2 in saliva.28 29 
Furthermore, the possible diagnostic use of saliva for several 
respiratory viruses including coronavirus has been supported by 
studies demonstrating a high sensitivity and specificity of saliva- 
based tests, with >90% concordance between saliva and naso-
pharyngeal swabs.30
Current studies from different groups have shown promising 
results on the possible use of saliva for detection of SARS- CoV-2 
RNA24 25 28 29 31–33 (table 2). The sensitivity of saliva- based 
SARS- CoV-2 RNA detection methods seem to be comparable 
to24 32 or better than that of nasopharyngeal swabs.25 Addition-
ally, saliva seems to be a good candidate for the detection of 
SARS- CoV-2 for cases with moderate- to- severe symptoms,25 
and for asymptomatic or mild cases.24 The latter is particularly 
important for the screening of the suspicious/asymptomatic cases 
and for the surveillance of the healthcare workers. Self- sampling 
of saliva could also be an option in large- scale population- based 
point- prevalence studies.
Being a non- invasive specimen type, saliva is well- suited for 
serial viral load monitoring. The SARS- CoV-2 load in the saliva 
is reported to be highest after the first week of symptom onset, 
followed by a gradual decline.25 28 29 This underlines that saliva 
is a good candidate for SARS- CoV-2 detection in earlier disease 
phase. The temporal profile of SARS- CoV-2 load in saliva has 
been reported to be more consistent25 as compared with that 
of nasopharyngeal swabs, suggesting its suitability for disease 
monitoring. Furthermore, saliva can be used for monitoring 
the response to antivirals in clinical trials.34 Nonetheless, saliva 
can also be a potential source of viral transmission, thereby 
requiring standard protocols for its collection and subsequent 
handling. In the light of these promising results, a saliva- 
based SARS- CoV-2 RNA detection assay has already obtained 
approval through the US Food and Drug Administration emer-
gency use authorisation.
Table 1 Advantages and disadvantages of saliva sampling
Advantages Disadvantages
Non- invasive approach for disease diagnosis and monitoring of general health. Not always reliable for measurement of certain markers.
Painless (no patient discomfort and anxiety for sampling). Contents of saliva can be influenced by the method of collection, degree of stimulation 
of salivary flow, interindividual variation and oral hygiene status.
Easy collection and applicable in remote areas. Serum markers can reach whole saliva in an unpredictable way.
Relatively cheap technology. Medications may affect salivary gland function and consequently the quantity and 
composition of saliva.
Cost- effective applicability for screening large populations. Possibility for degradation of salivary proteins due to presence of proteolytic enzymes.
Suitable for children, anxious/disabled/elderly patients.
Possible multisampling.
Safer collection for health professionals than other biological samples such as 
nasopharyngeal swabs and blood.
Cheap to store and ship.
Easy to handle.
No need for expensive equipment/instruments (swabs, suction tubes or special collection 
devices) for collection. Only needs a sterile container.
Table 2 Main findings of recent studies on SARS- CoV-2 detection in 
saliva samples by using RT- PCR.
Authors Main finding(s) related to salivary specimens
To et al28 91.7% of nasopharyngeal swab- diagnosed cases.
Live virus was detected in saliva using viral culture.
To et al29 87% of nasopharyngeal swab- diagnosed cases.
Salivary viral load was highest during the first week of symptom.
Azzi et al32 Detected in all nasopharyngeal swab- diagnosed cases.
Kojima et al24 Self- collected saliva and nasal swab had similar sensitivity as 
compared with the clinician- collected nasopharyngeal swabs
Wyllie et al25 Saliva is more sensitive and consistent than nasopharyngeal 
swabs
Williams et al31 84.6% of nasopharyngeal swab- diagnosed cases.
Viral load was higher in the nasopharyngeal swab.
Pasomub et al33 84.2% of nasopharyngeal swab- diagnosed cases.
Saliva might be an alternative specimen for COVID-19 diagnosis.
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Antibodies against SARS-CoV-2
Besides RT- PCR- based RNA detection of SARS- CoV-2, prelim-
inary studies have reported promising results for the detection 
of IgM and IgG against SARS- CoV-2 in serum/plasma samples 
of patients with SARS- CoV-2.35 Interestingly, the production of 
SARS- CoV- specific secretory IgA in the saliva of mice intrana-
sally immunised with SARS- CoV virus- like particles has been 
documented.36 Hence, it is reasonable to speculate that anti- 
SARS- CoV-2 antibodies might also be present in human saliva.
Viral antibodies have been detected in saliva and the immu-
nisation status of measles, rubella, mumps and hepatitis can 
be verified by analysing IgG, IgM and IgA in oral fluids.37 38 
Regarding SARS- CoV-2, to date only a study protocol aimed to 
analyse IgG, IgM and IgA in different biological fluids including 
self- collected saliva for rapid SARS- CoV-2 diagnosis has been 
published.39 However, there are so far no results describing the 
presence of antibodies against SARS- CoV-2 in human saliva. 
This clearly warrants future studies on the potential use of sali-
vary immunoglobulins for COVID-19 in diagnostics, disease 
progression and immunisation monitoring.
Saliva biomarkers—perspectives for COVID-19 diagnosis and 
prognosis
Salivary biomarkers and their role in point- of- care applications 
have highlighted the development of the use of more advanced 
technologies such as micro/nanoelectro- mechanical systems, 
paper- based technology, RNA- sequencing, liquid biopsy, fluo-
rescent biosensors, photometric and electrochemical methods, 
electric field- induced release and measurement method.12 40 
Contemporary available point- of- care can be delivered in form 
of small and portable smartphones or ‘lab- on- chips’.40
Coronaviruses, such as SARS- CoV and Middle East respi-
ratory syndrome (MERS)- CoV), have developed strategies to 
decrease or delay the production of interferon (IFN), triggering 
exuberant inflammatory responses leading to severe pulmo-
nary conditions.41 42 The host’s unregulated immune response 
and the production of inflammatory cytokines, known as ‘cyto-
kine storm’, are believed to correlate with disease severity and 
poor prognosis during SARS- CoV and MERS- CoV infection.41 
Several pro- inflammatory cytokines and chemokines, such as 
chemokine (C- C motif) ligand (CCL)-2, CCL-3, regulated on 
activation, normal T cell expressed and secreted (RANTES), 
interleukin (IL)-2 and IL-8, were highly expressed during 
MERS- CoV infection.41 Recent studies have reported that severe 
cases of COVID-19 exhibit increased plasma levels of IL-2, IL-6, 
IL-7, IL-10, granulocyte colony stimulating factor (GSCF), 
INF-γ-inducible protein-10 (IP-10), macrophage chemotactic 
protein 1, macrophage inflammatory protein- 1A and tumour 
necrosis factor-α compared with mild cases, indicating that the 
inflammatory response mediated by cytokine release is critical 
in the progression of COVID-19.42 43 Markers of the inflam-
matory process, such as cytokines and chemokines, can be 
measured in saliva. Such information has been suggested to be 
useful for the diagnosis and prognosis of both oral cavity and 
systemic diseases.13 Hence, it is possible to establish an inflam-
matory profile of COVID-19 by analysing inflammation- related 
biomarkers in saliva.
Unique proteomic, metabolic and/or lipid profiles in serum/
plasma have been suggested to be useful in stratification of fatal/
severe COVID-19 cases from the mild and healthy ones44; and 
to predict progression of COVID-19 patients from a milder 
from to severe stages.45 Interestingly, some of the identified 
biomarkers in these studies such as C reactive protein, lactate 
dehydrogenase, malic acid, guanosine monophosphate and 
proteins associated with macrophage, platelet degranulation 
and complement system pathways are shown to be present in 
saliva. These findings support the possible use of saliva- based 
metabolic/protein/lipid biomarkers as a non- invasive approach 
for patient stratification in COVID-19 disease.
Metabolomics is a strategy used in the study of small mole-
cules from the metabolic profile of cells, tissues or fluids, which 
help in the characterisation of a phenotype. These molecules, 
called biomarkers, are fundamental in clinical practice for deter-
mining the state of a disease.46 Thus, metabolomics has helped 
to identify biomarkers with diagnostic potential and description 
of metabolic pathways in the most diverse clinical situations, 
including those involving viral and bacterial pathogens, and 
more specifically viruses that cause respiratory diseases such as 
influenza47 48 and SARS.49 In a study by Wu et al,49 patients 
recovered from severe acute respiratory syndrome caused 
by SARS- CoV were recruited after 12 years of infection for 
metabolic evaluation of the consequences of the disease. The 
comparison of patients’ serum with healthy individuals showed 
differences in organic acids, amino acids, phospholipids, carni-
tine and inositol derivatives.49 These results exemplify the prac-
tical application of metabolomics in the evaluation of long- term 
outcomes.
MicroRNAs, non- coding RNAs of 20- nucleotide to 
22- nucleotide length, silencing gene expression by a transcript- 
specific target- mediate inhibitory activity, play a key role in several 
cellular processes including cell development and differentiation, 
immunity, cell metabolism, proliferation, apoptosis and cancer.50 
The relevance of monitoring microRNA is related to the fact that 
a single microRNA can be implicated in several cellular regula-
tory pathways, which involve different molecules. To date, there 
are studies reporting a particular microRNA upregulation and 
downregulation of nuclear factor-κB pathway and IFN pathway 
associated with several viruses including respiratory virus infec-
tion.51 In this context, studies reporting coronavirus (including 
SARS- CoV) regulation of cellular microRNA showed the over-
expression of miR-574- 5p and miR214 and regulation of miR-9 
and miR-98 with effect on apoptosis, cancer and autoimmune 
functions. Of note, SARS- CoV has been reported in the direct 
viral nucleocapsid downregulation of miR-223 and miR-98 
expression, with effect in pro- inflammatory cytokine produc-
tion.52 Additionally, in this context, since microRNAs associ-
ated with extracellular vesicles are known to be protected from 
enzymatic degradation, several studies have been focused on the 
investigation of the expression of microRNAs in extracellular 
vesicles obtained from saliva as potential biomarkers. Thus, the 
fact that microRNA present in biological fluid can reproduce the 
molecular event within the cellular context, make them a poten-
tial exhaustive marker to check the cell- infection status; this is 
especially important in a low replicative condition in which virus 
cannot be present in biological fluid,15 and provides an oppor-
tunity to assess virus pathological effect- associated diseases as in 
COVID-19.
Saliva mark of SARS-CoV-2 cell-receptor features in COVID-19
Its well known that SARS- CoV-2 infects host cells, including those 
in the respiratory tract lining, mainly using ACE2 receptor.53 It 
is reported that SARS- CoV spike protein S has a high affinity for 
the ACE2 receptor and is activated by host type II transmem-
brane serine protease TMPRSS2 on primary target cells to fulfil 
viral entry54 (figure 1). However, other host proteases such as 
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viral envelope glycoproteins in its furin- like cleavage site and 
enhancing infection with host cells.55
The use of ACE2 receptor by other coronaviruses to infect sali-
vary gland epithelial cells has been reported in rhesus macaques.6 
Additionally, in vitro analysis of RNA- seq profiles from four 
public and consensus datasets revealed the expression of ACE2 
receptor in human granular cells in salivary glands.26 These 
observations suggest that the salivary glands can be a reservoir 
for SARS- CoV-2 and contribute to the presence of the transmis-
sible form of viral infectious particles in saliva.56 Additionally, it 
is possible that the salivary glands can harbour latent COVID-19 
infection with possibility for subsequent reactivation. The latter 
suggestion clearly warrants further studies.
In addition to the salivary glands, ACE2 is abundantly expressed 
in the oral epithelial cells with highest expression in the tongue 
when compared with buccal and gingival tissues, T cells, B cells 
and oral fibroblasts.57 These results raise a possibility that oral 
epithelial cells can function as a host for SARS- CoV-2. Epithe-
lial cells in the oral mucosa are protected by a viscous mucous 
layer containing large glycoprotein macromolecules—mucins—
produced in the salivary glands, and water. Virus particles must 
penetrate the mucous layer to be able to infect the cells in the 
epithelial lining. In the respiratory tract, mucins in the mucous 
layer have been shown to play a significant role in protecting 
airway epithelium to influenza and respiratory syncytial virus.58 
Surprisingly, few studies have looked at the role of mucous layer 
covering human epithelial linings during SARS- CoV-2 infec-
tion. Case reports have described mucous plugging in the lungs 
in postmortem examinations of patients that have succumbed 
to COVID-19.59 Assuming that oral epithelial cells can be a 
possible route of entry for the SARS- CoV-2, studies are needed 
to understand the possible ways the virus particles penetrate the 
mucous layer and infect the underlying epithelial cells.
Of note, it has been reported by using airway epithelial cells in 
vitro that ACE2 is a human IFN- stimulated gene suggesting that 
SARS- CoV-2 could exploit IFN- driven upregulation of ACE2 as 
a mechanism to enhance viral infection and play a role in the 
development of COVID-19 pathogenesis.60 All of these find-
ings point out the potential interest in the investigation of saliva 
viral and host biomarkers as an opportunity to obtain a more 
complete molecular view of clinical relevance in the COVID-19 
risk assessment as well as to develop new therapeutic antiviral 
treatments.
CONCLUSION AND FUTURE PERSPECTIVES
Saliva- based testing can be an alternative to the more widely used 
nasopharyngeal/oropharyngeal swabs for COVID-19 diagnosis 
and disease monitoring. The use of saliva- based SARS- CoV-2 
testing offers several clinical advantages and is scientifically well 
founded. However, further studies will be key to understanding 
the mutual relationship between COVID-19 and saliva, leading 
to the adoption of less invasive diagnostic techniques and facili-
tating the application of molecular tests on a large scale, a central 
strategy for controlling the epidemic. The search for salivary 
biomarkers associated with the development and progression of 
COVID-19 could allow a better distinction between asymptom-
atic, mild, moderate or advanced disease. Knowledge of this kind 
might lead to the development of point- of- care devices, which 
can be extremely useful for understanding of the evolution of 
contagions and immunological responses in population studies.
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 ► Saliva has been described as a good candidate for diagnosis 
of COVID-19, showing sensitivity and specificity comparable 
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 ► Saliva is a non- invasive, easy to handle and with the 
possibility of self- collection body fluid—these characteristics 
are important in a pandemic scenario, leading to less 
exposure of healthcare professionals.
 ► Saliva biomarkers have a potential to be an important guide 
in COVID-19 prognosis, making possible the development of 
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